LCD Reference Article Response To Comments Article

Response to Comments: Micro-Invasive Glaucoma Surgery (MIGS)

A59912

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
National Government Services, Inc.	MAC - Part A	06101 - MAC A	J - 06	Illinois
National Government Services, Inc.	MAC - Part B	06102 - MAC B	J - 06	Illinois
National Government Services, Inc.	MAC - Part A	06201 - MAC A	J - 06	Minnesota
National Government Services, Inc.	MAC - Part B	06202 - MAC B	J - 06	Minnesota
National Government Services, Inc.	MAC - Part A	06301 - MAC A	J - 06	Wisconsin
National Government Services, Inc.	MAC - Part B	06302 - MAC B	J - 06	Wisconsin
National Government Services, Inc.	A and B and HHH MAC	13101 - MAC A	J - K	Connecticut
National Government Services, Inc.	A and B and HHH MAC	13102 - MAC B	J - K	Connecticut
National Government Services, Inc.	A and B and HHH MAC	13201 - MAC A	J - K	New York - Entire State
National Government Services, Inc.	A and B and HHH MAC	13202 - MAC B	J - K	New York - Downstate
National Government Services, Inc.	A and B and HHH MAC	13282 - MAC B	J - K	New York - Upstate
National Government Services, Inc.	A and B and HHH MAC	13292 - MAC B	J - K	New York - Queens
National Government Services, Inc.	A and B and HHH MAC	14111 - MAC A	J - K	Maine
National Government Services, Inc.	A and B and HHH MAC	14112 - MAC B	J - K	Maine
National Government Services, Inc.	A and B and HHH MAC	14211 - MAC A	J - K	Massachusetts
National Government Services, Inc.	A and B and HHH MAC	14212 - MAC B	J - K	Massachusetts
National Government Services, Inc.	A and B and HHH MAC	14311 - MAC A	J - K	New Hampshire
National Government Services, Inc.	A and B and HHH MAC	14312 - MAC B	J - K	New Hampshire
National Government Services, Inc.	A and B and HHH MAC	14411 - MAC A	J - K	Rhode Island
National Government Services, Inc.	A and B and HHH MAC	14412 - MAC B	J - K	Rhode Island
National Government Services, Inc.	A and B and HHH MAC	14511 - MAC A	J - K	Vermont
National Government Services, Inc.	A and B and HHH MAC	14512 - MAC B	J - K	Vermont

Article Information

General Information

Article ID
A59912

Article Title
Response to Comments: Micro-Invasive Glaucoma Surgery (MIGS)

Article Type
Response to Comments

Original Effective Date
11/17/2024

Retirement Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

Comments on Minimally Invasive Glaucoma Surgery (MIGS) were received during the Open Comment period by Palmetto, CGS, NGS, Noridian, and WPS. Responses to these comments are provided in this article.

Response To Comments

Number	Comment	Response
1	A comment letter was jointly written by American Academy of Ophthalmology (The Academy), American Glaucoma Society (AGS), American Society of Cataract and Refractive Surgery (ASCRS), and Outpatient Ophthalmic Surgery Society (OOSS). The express overall support of the Proposed policy: “The iterative public comment process has resulted in a proposed LCD which overall reflects current practice patterns and allows for the physician and patient to come to treatment decisions that work best for that unique patient. We also appreciate the added section on health care disparities in the policy, which recognizes the disproportionate disease burden of glaucoma on minorities, particularly African Americans and Latinos. Our organizations agree that more research is needed to better understand demographic differences in treatment and that future research must include more diverse study populations.” The following additional recommendations are made “We support coverage for one trabecular aqueous stent device per eye when performed in conjunction with phacoemulsification/intraocular lens placement (i.e., cataract surgery) and coverage for one subconjunctival space stent or trabecular aqueous stent device for the management of refractory glaucoma. While phacoemulsification/intraocular lens placement with a single MIGS procedure is indicated as covered in the limitations of coverage section, for clarity we think it makes more sense to include it in the Indications of Coverage section. Our organizations request that the MAC include a third coverage indication in the final LCD confirming that phacoemulsification/intraocular lens placement can be performed with a single MIGS…The proposed LCD does not provide coverage for phacoemulsification/intraocular lens placement performed with a combination of MIGS procedures (e.g., cataract + stent + canaloplasty or goniotomy) at the same time of service in the same eye. Although we understand why this limitation is in the policy at this time, our organizations call your attention to the growing body of evidence that shows improved outcomes and patient experience when MIGS procedures are combined. A 2023 study by Dickinson, et el. found significantly greater reduction in glaucoma medications while maintaining similar rates of intraocular pressure reduction and low complications when cataract surgery was combined with microstent and canaloplasty compared to cataract surgery and microstent alone.” Dickinson 2023 reference is submitted. They request case by case coverage of phacoemulsification/intraocular lens placement with more than one MIGS procedure. Editorial changes are recommended as well.	Thank you for your comments and overall support of the policy. Recommended editorial changes have been made throughout the policy. Additional literature was submitted and added to the LCD. The LCD allows phacoemulsification/intraocular lens placement to be performed with a single MIGS procedure. This clarification has been made in the LCD. There is not sufficient evidence to support the combination of phacoemulsification with multiple MIGS procedures in the same eye at the same time of service. The supporting literature has been added to the LCD but is limited to retrospective studies, short term follow-up, small sample sizes, incomplete data, risk of bias and multiple other factors discussed in the LCD that limit the reliability of these reports. Case by case coverage would not be appropriate as this is currently experimental and does not meet the definition of reasonable and necessary for Medicare coverage. We look forward to future research in this area and as additional evidence is developed it can be submitted through the LCD reconsideration process.
2	A comment letter was received from Sight Science with support of the proposed policy stating: “We appreciate that the proposed LCD is carefully tailored to assess the evidence supporting reasonable and necessary uses of trabecular aqueous stent devices.” They encourage MACs to “work closely with surgeons, specialty societies, patient advocates, and technology companies to ensure that Medicare policies support beneficiary access to safe, minimally invasive glaucoma surgical procedures, like the comprehensive aqueous outflow restoration procedure enabled by OMNI technology developed by Sight Sciences, to preserve sight for these patients.” They encourage inclusion of real-world results in evidence analysis explaining “The American Academy of Ophthalmology’s IRIS registry (Intelligent Research in Sight), is the largest specialty society clinical data registry in all of medicine and provides large scale “real world” evidence on the safety, IOP lowering efficacy, glaucoma medication reducing efficacy, and treatment durability of many MIGS procedures, including those performed using OMNI.”	Thank you for your comments and support of the proposed policy.
3	A comment letter from New World Medical (NWM), maker of several devices used in the treatment of glaucoma comments: “We support the Medical Directors proposed LCD in general, and specifically endorse the adopted definitions of canaloplasty and goniotomy. We request one addition, specifically, to be consistent with the citation found at the end of the goniotomy definition, at the end of the canaloplasty definition we suggest the addition of a citation to the American Academy of Ophthalmology page found at https://www.aao.org/practice-management/news-detail/canaloplasty (see Appendix A - showing identical language as in proposed LCD).”	Thank you for your comment and support of the policy. The citation has been added to the policy.
4	A comment letter from AbbVie request correction of supraconjuctival to subconjunctival in the indication for coverage section.	Thank you for commenting. This typographical error has been corrected.
5	A comment letter from Alcon is received and states: “Alcon urges the MACs to finalize its proposed determination that one trabecular aqueous stent device per eye which is approved for the treatment of adults with mild or moderate open-angle glaucoma (OAG) and a cataract when the individual is currently being treated with an ocular hypotensive medication and the procedure is being performed in conjunction with cataract surgery is reasonable and necessary. Alcon, however, is concerned that CGS’ proposal to non-cover multiple procedures on the same eye in the same day will unnecessarily limit physician treatment choices thereby harming beneficiaries.” The letter explains the complexity of glaucoma often requiring a combination of pharmacological and surgical intervention. They elaborate “Alcon urges CGS and the other MACs to revise the Proposed LCD to be inclusive of procedures without restricting diagnoses and disease stages across the procedures being offered. Specifically, we urge the MACs to permit multiple procedures on the same eye in the same day.” They explain scientific societies support access to new innovation to safely improve patient outcomes and preserve sites and “Alcon supports the position statements submitted by the American Academy of Ophthalmology, the American Glaucoma Society, and the American Society of Cataract and Refractive Surgery that preserve physician choice.” In conclusion they summarize: “Alcon believes medical policies need to be reflective of current and emerging treatment patterns, guided by clinical evidence and support of the scientific societies. ECPs must have the ability to make individualized treatment recommendations to best manage disease progression and minimize the threat of blindness in their patients. We appreciate consideration of Alcon’s perspectives and re-evaluation of the proposed LCD.”	Thank you for your comments. No additional literature was submitted with these comments. While we understand the importance of multiple treatment options in a complex condition such as glaucoma to be eligible for coverage the service must meet the definition of reasonable and necessary as defined by the Social Security Act. This requires demonstration of efficacy and improved outcomes for Medicare beneficiaries. There is not sufficient evidence to support multiple procedures in the same eye on the same day beyond what is already covered in the LCD. If such evidence is developed it can be submitted through the LCD reconsideration process.
6	A comment letter was received from a provider to NGS with overall support of the LCD. The author comments: To correct error “supraconjunctival” The header “Studies that compare IStent to surgical MIGS” is confusing. iStent is a “surgical MIGS” procedure. Either the intent is to compare iStent to other “MIGS procedures” or iStent and other stents to excisional angle procedures – goniotomy. In my opinion we should dump the term “MIGS” = not a good term that lumps together procedures which are not similar … and adopt more specific terms” with suggestions. I agree with using caution before covering multiple angle procedures – no good evidence for doing angle stents and goniotomy or angle stents and aqueous shunting and also does not seem like a logical combination for some combinations and can be a really good way of driving up costs if not regulated. I agree that Xen should be performed by ophthalmologists with experience in bleb management since much of success involves having some experience. We need to make Xen coverable for angle closure glaucomas. We do trabeculectomy for angle closure glaucomas and should have access to Xen for these.	Thank you for your comments and support of the policy. The typographical error was corrected to intended subconjunctival. The header was changed to “Studies that compare iStent to excisional angle procedures”. We appreciate the term MIGS is not specific but since this is what is utilized in the current literature and societal guidance and therefore retained in the policy. We agree however further clarification from the societies in the future may be beneficial. We appreciate your concern and agreement with the limitations on multiple procedures. We agree that that Xen should be performed by ophthalmologists with experience with bleb management. If evidence is developed demonstrating efficacy and improved outcome for XEN for angle closure glaucoma it can be submitted for expansion to coverage via the LCD reconsideration process.
7	A comment letter was received from Glaukos stating “Glaukos is appreciative of the detailed evidence review conducted by the MACs and we are supportive of the Proposed LCD and Draft Article as it relates to our December 2022 LCD Reconsideration Request associated with iStent infinite^®. We believe that, upon finalization, the coverage policy will further facilitate Medicare beneficiary access to high quality products and services to treat their sight threatening glaucoma disease.” They have additional recommendations as follows: Correction of typographical error supra -> subconjunctival and some additional editorial corrections. They recommend “Revise the third numbered item in the Limitations of Coverage to clarify the scope of the limitation so that it applies to the types of multiple MIGS procedures that are discussed in the Proposed LCD. Submission of new literature (Neuhann et al. 2024). Recommendations for the B&C Article “The Draft Article includes a section entitled “Multiple Procedure Limitations” that indicates that “reporting of a combination of MIGS procedures (other than phacoemulsification) at the same time of service in the same patient risks denial of the entire claim. A combination of services is more than 1 device or surgical technique applied at the same time.” This language is not consistent with the Proposed LCD and must be revised. As noted in Section I(C) above, we are concerned that the language might be misinterpreted to prevent coverage of multiple procedures like a cataract procedure and the insertion of an iStent. We do not see this as the MACs’ intent, but if a reader focused on the language about a combination of services being more than one surgical technique, the reader might misapprehend the intent.”	Thank you for your comments and support of the Proposed Policy. The typographical and editorial corrections have been made. The LCD language has been clarified that phacoemulsification can be performed with a single MIGS procedure (see Comment #1) in the LCD and B&C Article. The long-term data on iStent with cataract by Neuhann et al. was added to the LCD.

Coding Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

CPT/HCPCS Codes

Expand All | Collapse All

Please accept the License to see the codes.

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Related Local Coverage Documents
LCDs
L37244 - Micro-Invasive Glaucoma Surgery (MIGS)

Updated On	Effective Dates	Status
09/23/2024	11/17/2024 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: Micro-Invasive Glaucoma Surgery (MIGS)

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

CPT/HCPCS Codes

Please accept the License to see the codes.

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: Micro-Invasive Glaucoma Surgery (MIGS) (A59912)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS